FDA Sides With Panel In Downclassifying Antimicrobial Susceptibility Devices
This article was originally published in The Gray Sheet
Executive Summary
FDA will likely not require additional post-market surveillance from companies manufacturing automated short-term incubation cycle (STIC) antimicrobial susceptibility devices (ASDs), the agency says in the March 8 Federal Register.
You may also be interested in...
Antimicrobial Susceptibility Test System Reclassification Effective May 6
FDA's 1antimicrobial susceptibility test system final guidance recommends that essential and category agreement should be greater than 89.9%
Antimicrobial Susceptibility Test System Reclassification Effective May 6
FDA's 1antimicrobial susceptibility test system final guidance recommends that essential and category agreement should be greater than 89.9%
Interagency Task Force Identifies Point-of-Care Diagnostics As Top Priority
The ongoing research and development of new accurate, affordable, rapid diagnostic methods to facilitate appropriate use of antimicrobials should be a major government-wide priority, according to the Jan. 18 action plan issued by the Interagency Task Force on Antimicrobial Resistance.